<DOC>
	<DOCNO>NCT03035422</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) treatment option significant chance heal acute myeloid leukemia ( AML ) refractory multiple relapse chemotherapy . However , patient indication allo-HSC benefit two limitation : toxicity treatment graft shortage available .</brief_summary>
	<brief_title>Sequential Conditioning Haploidentical Transplantation Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>The goal evaluate efficacy safety combination SET follow haploidentical transplant post-transplant immune modulation prophylactic DLI patient refractory acute myeloid leukemia relapse . The main objective ass overall survival 2 year patient . Secondary objective : 1 . To evaluate efficacy therapeutic strategy term remission disease , incidence relapse relapse-free survival 2 . To evaluate non-relapse mortality 3 . To evaluate incidence acute chronic graft host disease ( GVHD ) 4 . To assess feasibility prophylactic injection donor lymphocyte ( pDLI ) 5 . To analyze post-transplant immune reconstitution Secondary endpoint : 1. partial complete remission rate standard criterion 90 day 6 , 12 24 month transplantation . Relapse incidence death related disease 90 day 6 , 12 24 month transplantation Leukemia-free survival 1 year 2 year transplantation 2 . Cumulative incidence death relate relapse 90 day , 1 year 2 year transplantation 3 . Cumulative incidence acute chronic graft host disease ( GVHD ) 4 . Number patient pDLI possible number pDLI / patient ; incidence , severity treatment possible secondary GVHD patient 5 . Study immune reconstitution post-transplant peripheral blood 30 , 90 180 day transplantation ( CD4 lymphocyte level , CD8 , T regulator , Natural Killer cell B cell ) Methodology , experimental design : Multicenter study routine care , prospective All patient receive , part marketing authorization product use , follow regimen : 1- sequential Packaging ( SET ) : 1. sequential chemotherapy : - Thiotepa 5 mg / kg / day 1 day ( D-13 ) - Cyclophosphamide 400 mg / m² / day 4 day ( J-12 J-9 ) - Etoposide 100 mg / m² / day 4 day ( J-12 J-9 ) 2 . Rest day J-8 J-6 3 . Reduced-intensity conditioning ( RIC ) - Fludarabine 30 mg / m² / day 5 day ( J-5 D-1 ) - Busulfan IV 3.2 mg / kg / day 2 day ( J-5 J-4 ) - Anti-lymphocyte serum ( Thymoglobuline ) 2.5 mg / kg / day 2 day ( J-3 J-2 ) 2 Graft transfusion : day D0 . A graft peripheral stem cell prefer . 3- Prevention GVHD : - Cyclophosphamide 50mg / kg / day day D + 3 D + 5 - Cyclosporine A ( CSA ; 3 mg / kg / day IV D + 6 ) - Mycophenolate mofetil ( MMF ; 30 mg / kg / day , maximum x2 1g / day day J + 6 ) 4- Care support : accord protocol center 5- lymphocyte injection prophylactic donor ( pDLI ) : accord protocol center . The following scheme propose : - In absence clinical contraindication ( GVHD ) , taper MMF day D + 35 D + 56 , taper CSA D + 62 D + 90 - pDLI : 3 injection D + 120 patient discontinue immunosuppressive therapy ≥ 1 month active GVHD history acute GVHD grade &gt; II . 6 . Feedback : baseline 1 , 3 , 6 , 12 24 month transplant ( engraftment , disease response , immune reconstitution , chimerism , GVHD , infection , quality life ) . The treatment evaluate strategy use usual care patient follow-up change .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients confirm diagnosis acute myeloid leukemia primary induction treatment failure ( persistent leukemia 2 cycle induction chemotherapy ) Patient age ≥ 18 &lt; 60 year Cardiac ejection fraction leave ventricle ≥ 45 % Lung function free diffusion capacity carbon monoxide ≥ 50 % predict value Creatinine clearance ≥ 50 ml / min depend CKDEPI formula Availability HLA haploidentical donor family Collection nonopposition Uncontrolled invasion CNS Availability HLA identical family donor agree donate hematopoietic stem cell OR nonrelated donor HLAcompatible 10/10 HLAA allele , B , C , DRB1 DQB1 available ready give 4 week make decision allograft Presence patient HLAspecific antibody direct antigen HLA haploidentical donor family Karnofsky score &lt; 70 % Patient HIV positive Hepatitis B C chronic active Uncontrolled infection time start pack Contraindication use treatment provide Protocol Previous history alloHSC No beneficiary social security scheme .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Allogenic cell stem transplant , Sequential chemotherapy Haploidentical transplant</keyword>
</DOC>